Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent High-Dose Icotinib + Docetaxel in EGFR Wild-Type NSCLC
NCT02191059Phase 2Unknown
- Sponsor
- Shandong Cancer Hospital
- Start
- Jul 2014
- Primary completion
- Jul 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of icotinib in non-small cell lung cancer (NSCLC), sponsored by Shandong Cancer Hospital. Status: unknown.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02191059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02191059.